Technical Analysis for MYOV - Myovant Sciences Ltd.

Grade Last Price % Change Price Change
B 22.83 2.93% 0.65
MYOV closed up 2.93 percent on Friday, September 17, 2021, on 1.17 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical MYOV trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 2.93%
Crossed Above 200 DMA Bullish 2.93%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.93%
Wide Bands Range Expansion 2.93%
Oversold Stochastic Weakness 2.93%
Older End-of-Day Signals for MYOV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Prostate Cancer Endocrine System Hormones Amines Fertility Infertility Reproduction Related Disorders Endometriosis Fibroids Advanced Prostate Cancer Gnrh Antagonists Male Infertility Pyrimidines Roivant Sciences Uterine Fibroid Uterine Fibroids Gonadotropin Releasing Hormone Antagonist

Is MYOV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 30.9
52 Week Low 13.42
Average Volume 690,308
200-Day Moving Average 22.17
50-Day Moving Average 21.80
20-Day Moving Average 23.68
10-Day Moving Average 23.94
Average True Range 1.13
ADX 22.33
+DI 25.93
-DI 27.59
Chandelier Exit (Long, 3 ATRs) 24.04
Chandelier Exit (Short, 3 ATRs) 23.70
Upper Bollinger Bands 27.18
Lower Bollinger Band 20.17
Percent B (%b) 0.38
BandWidth 29.63
MACD Line 0.23
MACD Signal Line 0.64
MACD Histogram -0.4135
Fundamentals Value
Market Cap 2.07 Billion
Num Shares 90.6 Million
EPS -3.98
Price-to-Earnings (P/E) Ratio -5.74
Price-to-Sales 64.89
Price-to-Book 70.01
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.17
Resistance 3 (R3) 24.14 23.68 23.94
Resistance 2 (R2) 23.68 23.34 23.69 23.87
Resistance 1 (R1) 23.25 23.13 23.47 23.28 23.79
Pivot Point 22.79 22.79 22.89 22.80 22.79
Support 1 (S1) 22.36 22.45 22.58 22.39 21.87
Support 2 (S2) 21.90 22.24 21.91 21.79
Support 3 (S3) 21.47 21.90 21.72
Support 4 (S4) 21.50